Iams Wealth Management LLC Purchases 72 Shares of Amgen Inc. (NASDAQ:AMGN)

Iams Wealth Management LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,537 shares of the medical research company’s stock after buying an additional 72 shares during the quarter. Iams Wealth Management LLC’s holdings in Amgen were worth $818,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Hershey Financial Advisers LLC acquired a new position in Amgen during the second quarter valued at approximately $30,000. nVerses Capital LLC acquired a new position in Amgen during the second quarter valued at approximately $31,000. Bbjs Financial Advisors LLC acquired a new position in Amgen during the second quarter valued at approximately $33,000. Matrix Trust Co acquired a new position in Amgen during the third quarter valued at approximately $36,000. Finally, FSA Wealth Management LLC lifted its position in shares of Amgen by 182.0% in the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after buying an additional 91 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Down 1.1 %

Shares of AMGN opened at $324.62 on Tuesday. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85. The business’s fifty day moving average is $326.05 and its 200-day moving average is $311.20. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The firm has a market cap of $174.14 billion, a price-to-earnings ratio of 46.37, a PEG ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter in the previous year, the business posted $5.00 EPS. The company’s revenue for the quarter was up 20.1% on a year-over-year basis. Equities analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.77%. Amgen’s payout ratio is 128.57%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AMGN shares. Barclays raised their price objective on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price objective (up from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. Morgan Stanley cut their price objective on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. Finally, Bank of America raised their price objective on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $326.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.